Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy

Pancreatology

Volumn 12, Issue 5, 2012, Pages 409-416

  Tsutsumi, Koichiro ^a   Kawamoto, Hirofumi ^b   Hirao, Ken ^c   Sakakihara, Ichiro ^a   Yamamoto, Naoki ^a   Noma, Yasuhiro ^a   Fujii, Masakuni ^a   Kato, Hironari ^a   Ogawa, Tsuneyoshi ^c   Ishida, Etsuji ^d   Kuwaki, Kenji ^a   Nouso, Kazuhiro ^a   Okada, Hiroyuki ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

Diagnosis; Gemcitabine; Pancreas; Pancreatic cancer; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN; DUPAN 2; GEMCITABINE; SPAN 1 PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 84873099295     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.07.009     Document Type: Article

References (26)

1. Schnall SF, Macdonald JS Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996; 23: 220-8. (Pubitemid 26120242)
2. Nakai Y, Isayama H, Sasaki T., Sasahira N, Ito Y, Kogure H., et al Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas 2010; 39: 989-93.
3. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trials. J Clin Oncol 1997; 15: 2403-13. (Pubitemid 27251144)
4. Pelzer U, Schwaner I, Stieler J., Adler M, Seraphin J, Dörken B, et al Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-81.
5. Therasse P, Arbuck SG, Eisenhauer E.A., Wanders J., Kaplan RS, Rubinstein L, et al New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16. (Pubitemid 30099779)
6. Stephens CD. Gemcitabine: a new approach to treating pancreatic cancer. Oncol Nurs Forum 1998; 25: 87-93.
7. Brambs HJ, Claussen CD Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy 1993; 25: 58-68. (Pubitemid 23099124)
8. Reni M, Cereda S, Balzano G., Passoni P, Rognone A, Fugazza C., et al Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115: 2630-9.
9. Stemmler J, Stieber P, Szymala A.M., Schalhorn A., Schermuly MM, Wilkowski R, et al Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 2003; 26: 462-7. (Pubitemid 37409891)
10. Ko AH, Hwang J, Venook A.P., Abbruzzese JL, Bergsland EK, Tempero MA Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005; 93: 195-9. (Pubitemid 41133205)
11. Halm U, Schumann T, Schiefke I., Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-6. (Pubitemid 30128852)
12. Maisey NR, Norman AR, Hill A, Massey A., Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005; 93: 740-3. (Pubitemid 41486431)
13. Ziske C, Schlie C, Gorschluter M., Glasmacher A, Mey U, Strehl J., et al Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-7. (Pubitemid 37386593)
14. Boeck S, Stieber P, Holdenrieder S., Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70: 255-64. (Pubitemid 44670165)
15. Ishii H, Okada S, Sato T., Wakasugi H, Saisho H, Furuse J., et al CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997; 44: 279-83. (Pubitemid 27096053)
16. Hirao K, Kawamoto H, Sakakihara I., Noma Y, Yamamoto N, Harada R., et al A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity. Int J Clin Oncol 2011; 16: 637-45.
17. Koprowski H, Steplewski Z, Mitchell K., Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-72.
18. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-5. (Pubitemid 20140602)
19. Ritts RE, Pitt HA CA19-9 in pancreatic cancer. Surg Oncol Clin North Am 1999; 7: 93-101.
20. Gogas H, Lofts FJ, Evans T.R., Daryanani S., Mansi JL Are serial measurement of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998; 77: 325-8. (Pubitemid 28029551)
21. Saad ED, Machado MC, Wajsbrot D, Abramoff R., Hoff PM, Tabacof J, et al Pretreatment CA19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002; 32: 35-41. (Pubitemid 36323101)
22. Hess V, Glimelius B, Grawe P., Dietrich D, Bodoky G, Ruhstaller T., et al CA19-9 tumor marker response in patients with advanced pancreatic cancer enrolled in a randomized controlled trial. Lancet Oncol 2008; 9: 132-8.
23. Rocha Lima C.M., Savarese D, Bruckner H., Dudek A, Eckardt J, Hainsworth J., et al Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-91. (Pubitemid 34177423)
24. Rocha Lima C.M., Green MR, Rotche R, Miller Jr WH, Jeffrey GM, Cisar LA, et al Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-83. (Pubitemid 41095218)
25. Tempero MA, Uchida E, Takasaki H., Burnett DA, Steplewski Z, Pour PM Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47: 5501-3. (Pubitemid 17152971)
26. Kawa S, Tokoo M, Oguchi H., Furuta S, Homma T, Hasegawa Y., et al Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas 1994; 9: 692-7. (Pubitemid 24317818)